PD-L1 过表达与非小细胞肺癌患者生存：一项荟萃分析。
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.
机构信息
Department of Respiratory Medicine, Jinling Hospital, Nanjing University School of Medical, Nanjing 210002, China.
出版信息
Transl Lung Cancer Res. 2015 Apr;4(2):203-8. doi: 10.3978/j.issn.2218-6751.2015.03.02.
Abstract
BACKGROUND
Observational studies on the prognostic role of programmed cell death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) are controversial.
METHODS
To clarify the impact of PD-L1 in NSCLC survival, we performed this meta-analysis that included eligible studies. The combined hazard ratios (HR) and their corresponding 95% confidence intervals (CIs) were calculated in terms of overall survival.
RESULTS
A total of five studies with 877 patients were evaluable for this meta-analysis. Our results suggested that PD-L1 overexpression had a poor impact on survival of patients with NSCLC, the HR (95% CI) was 1.43 (1.24-1.63) overall, 1.51 (1.24-1.7954) in Asian patients, 1.35 (1.08-1.63) in non-Asian patients. Moreover, there was no heterogeneity between the studies.
CONCLUSIONS
PD-L1 overexpression indicates a poor prognosis for patients with NSCLC.
摘要
背景
关于程序性死亡配体 1（PD-L1）在非小细胞肺癌（NSCLC）中的预后作用的观察性研究结果存在争议。
方法
为了阐明 PD-L1 在 NSCLC 生存中的影响，我们进行了这项荟萃分析，其中包括符合条件的研究。根据总生存率计算合并风险比（HR）及其相应的 95%置信区间（CI）。
结果
共有五项研究，共 877 名患者可用于本荟萃分析。我们的结果表明，PD-L1 过表达对 NSCLC 患者的生存有不良影响，HR（95%CI）总体为 1.43（1.24-1.63），亚洲患者为 1.51（1.24-1.7954），非亚洲患者为 1.35（1.08-1.63）。此外，研究之间没有异质性。
结论
PD-L1 过表达表明 NSCLC 患者预后不良。
相似文献
1
PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.PD-L1 过表达与非小细胞肺癌患者生存：一项荟萃分析。
Transl Lung Cancer Res. 2015 Apr;4(2):203-8. doi: 10.3978/j.issn.2218-6751.2015.03.02.
2
Prognostic value of programmed cell death-ligand 1 expression in patients with non-small-cell lung cancer: evidence from an updated meta-analysis.程序性细胞死亡配体1表达在非小细胞肺癌患者中的预后价值：来自一项更新的荟萃分析的证据
Onco Targets Ther. 2015 Dec 1;8:3595-601. doi: 10.2147/OTT.S91469. eCollection 2015.
3
The Impact of Programmed Death-Ligand 1 Expression on the Prognosis of Early Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis of Literatures.程序性死亡配体1表达对早期切除的非小细胞肺癌预后的影响：文献的荟萃分析
Front Oncol. 2021 Feb 23;11:567978. doi: 10.3389/fonc.2021.567978. eCollection 2021.
4
The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis.PD-L1表达对非小细胞肺癌患者的预后价值：一项荟萃分析。
Eur J Surg Oncol. 2015 Apr;41(4):450-6. doi: 10.1016/j.ejso.2015.01.020. Epub 2015 Jan 31.
5
The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis.程序性细胞死亡配体 1 表达在非小细胞肺癌患者中的预后作用：一项更新的荟萃分析。
Clin Chim Acta. 2018 Jul;482:101-107. doi: 10.1016/j.cca.2018.03.038. Epub 2018 Mar 31.
6
Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis.程序性细胞死亡配体1（PD-L1）表达在非小细胞肺癌患者中的临床病理及预后意义：一项荟萃分析
J Thorac Dis. 2015 Mar;7(3):462-70. doi: 10.3978/j.issn.2072-1439.2015.02.13.
7
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
8
Prognostic value of the expression of estrogen receptor β in patients with non-small cell lung cancer: a meta-analysis.雌激素受体 β 在非小细胞肺癌患者中的表达的预后价值：一项荟萃分析。
Transl Lung Cancer Res. 2016 Apr;5(2):202-7. doi: 10.21037/tlcr.2016.04.04.
9
The role of SOX-2 on the survival of patients with non-small cell lung cancer.SOX-2在非小细胞肺癌患者生存中的作用。
J Thorac Dis. 2015 Jul;7(7):1113-8. doi: 10.3978/j.issn.2072-1439.2015.07.14.
10
A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer.一项比较抗程序性死亡蛋白1（Anti-PD-1）与抗程序性死亡配体1（Anti-PD-L1）在非小细胞肺癌中疗效和安全性的网状Meta分析。
J Cancer. 2018 Mar 10;9(7):1200-1206. doi: 10.7150/jca.22361. eCollection 2018.
引用本文的文献
1
Severe thyroiditis induced by sintilimab monotherapy in a patient with non-small cell lung cancer: a case report and literature review.信迪利单抗单药治疗非小细胞肺癌患者引起的严重甲状腺炎：一例病例报告及文献综述
Front Immunol. 2025 Feb 25;16:1548452. doi: 10.3389/fimmu.2025.1548452. eCollection 2025.
2
The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.顺铂在调节肿瘤免疫微环境中的作用及其联合治疗策略：增强抗肿瘤疗效的新方法。
Ann Med. 2025 Dec;57(1):2447403. doi: 10.1080/07853890.2024.2447403. Epub 2025 Jan 6.
3
Prognostic value of programmed cell death ligand 1 (PD-L1) expression in patients with stage III non-small cell lung cancer under different treatment types: a retrospective study.不同治疗类型下 III 期非小细胞肺癌患者程序性死亡配体 1（PD-L1）表达的预后价值：一项回顾性研究。
Einstein (Sao Paulo). 2024 Jun 24;22:eAO0575. doi: 10.31744/einstein_journal/2024AO0575. eCollection 2024.
4
PD-L1 expression and microsatellite instability (MSI) in cancer of unknown primary site.原发灶不明的癌症中的 PD-L1 表达和微卫星不稳定性 (MSI)。
Int J Clin Oncol. 2024 Jun;29(6):726-734. doi: 10.1007/s10147-024-02494-3. Epub 2024 Mar 25.
5
Immune-related adverse events associated with nab-paclitaxel/paclitaxel combined with immune checkpoint inhibitors: a systematic review and network meta-analysis.免疫相关不良事件与纳武利尤单抗/紫杉醇联合免疫检查点抑制剂相关：系统评价和网络荟萃分析。
Front Immunol. 2023 Jul 14;14:1175809. doi: 10.3389/fimmu.2023.1175809. eCollection 2023.
6
Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer.程序性死亡配体 1（PD-L1）表达对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）治疗表皮生长因子受体（EGFR）突变型非小细胞肺癌疗效的影响。
Thorac Cancer. 2023 Aug;14(24):2327-2337. doi: 10.1111/1759-7714.15021. Epub 2023 Jul 5.
7
Prognostic Role of CD68 and CD163 Tumour-Associated Macrophages and PD-L1 Expression in Oral Squamous Cell Carcinoma: A Meta-Analysis.CD68 和 CD163 肿瘤相关巨噬细胞和 PD-L1 表达在口腔鳞状细胞癌中的预后作用：一项荟萃分析。
Br J Biomed Sci. 2023 Jun 16;80:11065. doi: 10.3389/bjbs.2023.11065. eCollection 2023.
8
Molecular Farming of Pembrolizumab and Nivolumab.泊洛妥珠单抗和纳武利尤单抗的分子农业生产。
Int J Mol Sci. 2023 Jun 12;24(12):10045. doi: 10.3390/ijms241210045.
9
The Effects of GCSF Primary Prophylaxis on Survival Outcomes and Toxicity in Patients with Advanced Non-Small Cell Lung Cancer on First-Line Chemoimmunotherapy: A Sub-Analysis of the Spinnaker Study.GCSF 初级预防对一线化疗免疫治疗的晚期非小细胞肺癌患者生存结局和毒性的影响：Spinnaker 研究的亚分析。
Int J Mol Sci. 2023 Jan 16;24(2):1746. doi: 10.3390/ijms24021746.
10
A systematic review and network meta-analysis of first-line immune checkpoint inhibitor combination therapies in patients with advanced non-squamous non-small cell lung cancer.系统评价和网络荟萃分析一线免疫检查点抑制剂联合治疗晚期非鳞状非小细胞肺癌患者。
Front Immunol. 2022 Oct 26;13:948597. doi: 10.3389/fimmu.2022.948597. eCollection 2022.
本文引用的文献
1
Protein expression of programmed death 1 ligand 1 and ligand 2 independently predict poor prognosis in surgically resected lung adenocarcinoma.程序性死亡受体 1 配体 1 和配体 2 的蛋白表达独立预测手术切除的肺腺癌预后不良。
Onco Targets Ther. 2014 Apr 12;7:567-73. doi: 10.2147/OTT.S59959. eCollection 2014.
2
Update on immune checkpoint inhibitors in lung cancer.肺癌免疫检查点抑制剂的最新进展。
Cancer Control. 2014 Jan;21(1):80-9. doi: 10.1177/107327481402100112.
3
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.程序性死亡受体 1（PD-1）及其配体（PD-L1）在血液系统恶性肿瘤患者 T 细胞免疫抑制中的作用。
J Hematol Oncol. 2013 Sep 30;6(1):74. doi: 10.1186/1756-8722-6-74.
4
Programmed death ligand-1 expression in non-small cell lung cancer.程序性死亡配体-1 在非小细胞肺癌中的表达。
Lab Invest. 2014 Jan;94(1):107-16. doi: 10.1038/labinvest.2013.130. Epub 2013 Nov 11.
5
Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.程序性死亡蛋白1配体1在非小细胞肺癌患者中的表达的临床意义：一项5年随访研究
Tumori. 2012 Nov;98(6):751-5. doi: 10.1177/030089161209800612.
6
Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.COX-2 表达对非小细胞肺癌患者预后的预测价值：系统评价和荟萃分析。
J Thorac Dis. 2013 Feb;5(1):40-7. doi: 10.3978/j.issn.2072-1439.2013.01.02.
7
Tumor-induced CD8+ T-cell dysfunction in lung cancer patients.肺癌患者中肿瘤诱导的CD8 + T细胞功能障碍。
Clin Dev Immunol. 2012;2012:741741. doi: 10.1155/2012/741741. Epub 2012 Oct 17.
8
Predicting survival of patients with resectable non-small cell lung cancer: Beyond TNM.预测可切除非小细胞肺癌患者的生存率：超越TNM分期。
J Thorac Dis. 2012 Apr 1;4(2):214-6. doi: 10.3978/j.issn.2072-1439.2012.03.06.
9
Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer.基因表达检测作为早期非小细胞肺癌的预后和预测标志物
J Thorac Dis. 2012 Apr 1;4(2):212-3. doi: 10.3978/j.issn.2072-1439.2012.03.02.
10
Prognostic value of the ratio of ground glass opacity on computed tomography in small lung adenocarcinoma: A meta-analysis.计算机断层扫描中磨玻璃密度比值对小肺腺癌的预后价值：一项荟萃分析。
J Thorac Dis. 2012 Jun 1;4(3):265-71. doi: 10.3978/j.issn.2072-1439.2012.05.09.
Zotero 插件